EP3954713A3 - Anticorps bispécifiques se liant à cd38 et cd3 - Google Patents

Anticorps bispécifiques se liant à cd38 et cd3 Download PDF

Info

Publication number: EP3954713A3
Authority: EP; European Patent Office
Prior art keywords: bind; bispecific antibodies; heterodimeric; antibodies; proteins including
Prior art date: 2014-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21172032.1A

Other languages

German (de)

English (en)

Other versions

EP3954713A2 (fr

Inventor

Matthew J. Bernett

Seung Y. Chu

Gregory Moore

John Desjarlais

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Xencor Inc

Original Assignee

Xencor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-28

Filing date

2015-03-30

Publication date

2022-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53053074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3954713(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-30 Application filed by Xencor Inc filed Critical Xencor Inc

2022-02-16 Publication of EP3954713A2 publication Critical patent/EP3954713A2/fr

2022-03-30 Publication of EP3954713A3 publication Critical patent/EP3954713A3/fr

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP21172032.1A 2014-03-28 2015-03-30 Anticorps bispécifiques se liant à cd38 et cd3 Pending EP3954713A3 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201461972172P	2014-03-28	2014-03-28
US201462025974P	2014-07-17	2014-07-17
US201462025931P	2014-07-17	2014-07-17
EP15720820.8A EP3122781B1 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
PCT/US2015/023411 WO2015149077A1 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
EP19213494.8A EP3699195A3 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
EP19213494.8A Division EP3699195A3 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
EP15720820.8A Division EP3122781B1 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3

Publications (2)

Publication Number	Publication Date
EP3954713A2 EP3954713A2 (fr)	2022-02-16
EP3954713A3 true EP3954713A3 (fr)	2022-03-30

Family

ID=53053074

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP15720820.8A Active EP3122781B1 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
EP19213494.8A Withdrawn EP3699195A3 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
EP21172032.1A Pending EP3954713A3 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP15720820.8A Active EP3122781B1 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3
EP19213494.8A Withdrawn EP3699195A3 (fr)	2014-03-28	2015-03-30	Anticorps bispécifiques se liant à cd38 et cd3

Country Status (32)

Country	Link
US (3)	US9822186B2 (fr)
EP (3)	EP3122781B1 (fr)
JP (3)	JP6775422B2 (fr)
KR (3)	KR102327996B1 (fr)
CN (2)	CN111410691B (fr)
AP (1)	AP2016009475A0 (fr)
AU (2)	AU2015237184B2 (fr)
BR (1)	BR112016022385A2 (fr)
CA (1)	CA2943621A1 (fr)
CL (1)	CL2016002460A1 (fr)
CR (1)	CR20160506A (fr)
CY (1)	CY1123236T1 (fr)
DK (1)	DK3122781T3 (fr)
EA (1)	EA201691925A1 (fr)
ES (1)	ES2775431T3 (fr)
HR (1)	HRP20200164T1 (fr)
HU (1)	HUE048734T2 (fr)
IL (1)	IL248007B (fr)
LT (1)	LT3122781T (fr)
ME (1)	ME03666B (fr)
MX (2)	MX385936B (fr)
PE (1)	PE20161431A1 (fr)
PH (1)	PH12016501908A1 (fr)
PL (1)	PL3122781T3 (fr)
PT (1)	PT3122781T (fr)
RS (1)	RS59907B1 (fr)
SG (2)	SG11201607983YA (fr)
SI (1)	SI3122781T1 (fr)
SM (1)	SMT202000141T1 (fr)
TN (1)	TN2017000532A1 (fr)
UA (1)	UA119167C2 (fr)
WO (1)	WO2015149077A1 (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011028952A1 (fr)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CN103052649B (zh)	2010-07-29	2015-12-16	Xencor公司	具有修改的等电点的抗体
EP4279513A3 (fr)	2010-11-30	2024-02-28	Chugai Seiyaku Kabushiki Kaisha	Agent thérapeutique induisant la cytotoxicité
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
CN105051069B (zh)	2013-01-14	2019-12-10	Xencor股份有限公司	新型异二聚体蛋白
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US9738722B2 (en)	2013-01-15	2017-08-22	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10544187B2 (en)	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
EP3122781B1 (fr)	2014-03-28	2020-01-01	Xencor, Inc.	Anticorps bispécifiques se liant à cd38 et cd3
CA2943943C (fr)	2014-04-07	2023-01-10	Chugai Seiyaku Kabushiki Kaisha	Molecule d'immunoactivation de liaison a un antigene
BR112016026299A2 (pt) *	2014-05-13	2018-02-20	Chugai Seiyaku Kabushiki Kaisha	molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
AU2015353416C1 (en) *	2014-11-26	2022-01-27	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CD38
EP3223845B1 (fr)	2014-11-26	2021-05-19	Xencor, Inc.	Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (fr)	2014-12-22	2017-11-01	Xencor, Inc.	Anticorps trispécifiques
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
CA2984134A1 (fr) *	2015-05-08	2016-11-17	Xencor, Inc.	Anticorps heterodimeriques se liant aux antigenes cd3 et tumoraux
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
ES2894304T3 (es)	2015-10-25	2022-02-14	Sanofi Sa	Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
JP6931329B2 (ja)	2015-11-18	2021-09-01	中外製薬株式会社	免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (fr)	2015-11-18	2017-05-26	中外製薬株式会社	Procédé pour renforcer la réponse immunitaire humorale
WO2017100372A1 (fr)	2015-12-07	2017-06-15	Xencor, Inc.	Anticorps hétérodimèes se liant à cd3 et psma
LT3411404T (lt)	2016-02-03	2022-12-27	Amgen Research (Munich) Gmbh	Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
MX2018010824A (es) *	2016-03-08	2019-05-15	Maverick Therapeutics Inc	Proteinas de union inducibles y metodos de uso.
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
EP3998285B1 (fr) *	2016-03-25	2025-01-22	Biomunex Pharmaceuticals	Molécules de liaison pour cd38 et pd-l1
EP4257193A3 (fr)	2016-04-13	2024-01-24	Sanofi	Protéines de liaison trispécifiques et/ou trivalentes
TWI788286B (zh)	2016-04-13	2023-01-01	法商賽諾菲公司	三特異性和/或三價結合蛋白
AU2017250358B2 (en)	2016-04-15	2023-06-01	Alpine Immune Sciences, Inc.	ICOS ligand variant immunomodulatory proteins and uses thereof
CN109563166B (zh)	2016-04-28	2022-12-20	拜奥穆尼克斯制药	靶向egfr和her2的双特异性抗体
EP3464365A1 (fr)	2016-06-01	2019-04-10	Xencor, Inc.	Anticorps bispécifiques qui lient cd123 et cd3
EP3464370A1 (fr)	2016-06-01	2019-04-10	Xencor, Inc.	Anticorps bispécifiques qui se lient à cd20 et cd3 destinés à être utilisés dans le traitement d'un lymphome
WO2017218707A2 (fr) *	2016-06-14	2017-12-21	Xencor, Inc.	Anticorps inhibiteurs de points de contrôle bispécifiques
CA3029209A1 (fr)	2016-06-21	2017-12-28	Teneobio, Inc.	Anticorps se liant a cd3
US10316088B2 (en) *	2016-06-28	2019-06-11	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
JP2019530641A (ja) *	2016-07-19	2019-10-24	アイベントラス・インコーポレイテッドＩｂｅｎｔｒｕｓ，Ｉｎｃ．	二重特異性タンパク質およびその製造方法
TWI781108B (zh)	2016-07-20	2022-10-21	比利時商健生藥品公司	抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (fr)	2016-08-30	2018-03-08	Xencor, Inc.	Anticorps immunomodulateurs bispécifiques qui se lient à des récepteurs de costimulation et de points de contrôle
UA126384C2 (uk)	2016-09-14	2022-09-28	Тенеобіо, Інк.	Антитіло, яке зв'язує cd3
CA3037694C (fr)	2016-09-30	2023-11-14	Centre National De La Recherche Scientifique	Marqueurs cellulaires
US12188935B2 (en)	2016-09-30	2025-01-07	Centre National De La Recherche Scientifique	Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
MA46534A (fr)	2016-10-14	2019-08-21	Xencor Inc	Protéines de fusion fc hétérodimères il15/il15r
NZ795790A (en)	2016-12-21	2025-11-28	Teneobio Inc	Anti-BCMA heavy chain-only antibodies
EP3575319A4 (fr)	2016-12-30	2021-03-10	Shanghai Sinobio Biotech Co., Ltd.	Molécule bifonctionnelle et son utilisation
CN108264562B (zh) *	2016-12-30	2021-08-10	惠和生物技术(上海)有限公司	一种结合cd3和t细胞正共刺激分子的双功能分子及其应用
HUE070957T2 (hu) *	2017-02-16	2025-07-28	Sonnet Biotherapeutics Inc	Albuminkötõ domén fúziós fehérjék
WO2018178101A1 (fr)	2017-03-27	2018-10-04	Biomunex Pharmaceuticals	Anticorps multispécifiques stables
AU2018247767B2 (en)	2017-04-03	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to STEAP-1
WO2018223004A1 (fr)	2017-06-01	2018-12-06	Xencor, Inc.	Anticorps bispécifiques se liant à cd20 et cd3
AU2018275109A1 (en)	2017-06-01	2020-01-02	Xencor, Inc.	Bispecific antibodies that bind CD 123 CD3
KR20250025514A (ko)	2017-06-08	2025-02-21	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
CN111051344B (zh)	2017-06-08	2023-10-27	黑带医疗有限公司	Cd38调节抗体
US11970540B2 (en)	2017-06-20	2024-04-30	Teneobio, Inc.	Anti-BCMA heavy chain-only antibodies
CA3065951A1 (fr)	2017-06-20	2018-12-27	Teneoone, Inc.	Anticorps uniquement a chaines lourdes anti-bcma
WO2019000223A1 (fr) *	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation
WO2019006472A1 (fr)	2017-06-30	2019-01-03	Xencor, Inc.	Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AU2018316521B2 (en)	2017-08-16	2025-01-30	Black Belt Therapeutics Limited	CD38 modulating antibody
WO2019035938A1 (fr)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Molécules multispécifiques se liant à bcma et leurs utilisations
AU2018316522B2 (en)	2017-08-16	2025-02-20	Black Belt Therapeutics Limited	CD38 antibody
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
IL302613B2 (en)	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions
CA3075399A1 (fr) *	2017-09-13	2019-03-21	Teneobio, Inc.	Anticorps a chaine lourde se liant a des exoenzymes
US11186649B2 (en)	2017-10-10	2021-11-30	Sanofi	Anti-CD38 antibodies and methods of use
IL320945A (en) *	2017-10-18	2025-07-01	Alpine Immune Sciences Inc	Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
AU2018366199A1 (en)	2017-11-08	2020-05-28	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MA51291A (fr)	2017-12-19	2020-10-28	Xencor Inc	Protéines de fusion il-2 fc modifiées
MA51747A (fr)	2018-02-08	2020-12-16	Amgen Inc	Formulation d'anticorps pharmaceutique à ph faible
EA202092302A1 (ru) *	2018-04-02	2021-02-02	Бристол-Майерс Сквибб Компани	Антитела к trem-1 и их применения
CA3096052A1 (fr)	2018-04-04	2019-10-10	Xencor, Inc.	Anticorps heterodimeres qui se lient a la proteine d'activation des fibroblastes
SG11202010159RA (en)	2018-04-18	2020-11-27	Xencor Inc	Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
MX2020010910A (es)	2018-04-18	2021-02-09	Xencor Inc	Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
US20190352362A1 (en)	2018-04-18	2019-11-21	Xencor, Inc.	LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
CA3097741A1 (fr)	2018-04-18	2019-10-24	Xencor, Inc.	Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3
WO2019210147A1 (fr)	2018-04-27	2019-10-31	Xencor, Inc.	Dosage d'un anticorps bispécifique qui se lie à cd123 et cd3
WO2019224385A2 (fr) *	2018-05-24	2019-11-28	Glenmark Pharmaceuticals S.A.	Anticorps bispécifiques combinés et thérapies immuno-oncologiques
AU2019276578A1 (en)	2018-06-01	2021-01-14	Compugen Ltd	Anti-PVRIG/anti-TIGIT bispecific antibodies and methods of use
UY38289A (es)	2018-07-02	2020-01-31	Amgen Inc	Proteína de unión al antígeno anti-steap1
WO2020018556A1 (fr) *	2018-07-16	2020-01-23	Amgen Inc.	Procédé de traitement du myélome multiple
CA3115096A1 (fr)	2018-10-03	2020-04-09	Xencor, Inc.	Proteines de fusion fc heterodimeres d'il-12
JP7462621B2 (ja)	2018-10-09	2024-04-05	サノフイ	三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
MA53862A (fr)	2018-10-12	2022-01-19	Xencor Inc	Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
US20210388106A1 (en) *	2018-10-26	2021-12-16	Teneobio, Inc.	Heavy chain antibodies binding to cd38
AU2019395841B2 (en)	2018-12-14	2025-02-27	Morphosys Ag	Antibody formulations
EP3897853A1 (fr)	2018-12-20	2021-10-27	Xencor, Inc.	Protéines de fusion fc hétérodimères ciblées contenant les il-15/il-15ra et des domaines de liaison à l'antigène nkg2d
CN113811549A (zh)	2019-02-21	2021-12-17	Xencor股份有限公司	非靶向和靶向性il-10 fc融合蛋白
CA3131036A1 (fr) *	2019-02-22	2020-08-27	Wuhan Yzy Biopharma Co., Ltd.	Fragment de liaison a l'antigene cd3 et application de celui-ci
BR112021016955A2 (pt)	2019-03-01	2021-11-23	Xencor Inc	Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
EP4592313A3 (fr)	2019-03-05	2025-11-19	Takeda Pharmaceutical Company Limited	Protéines de liaison à activation conditionnelle restreinte
US20210079094A1 (en)	2019-03-29	2021-03-18	Xencor, Inc.	Dosing of a bispecific antibody that binds pd1 and ctla4
KR20210149076A (ko)	2019-04-05	2021-12-08	테네오바이오, 인코포레이티드	Psma에 결합하는 중쇄 항체
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
WO2020236655A1 (fr)	2019-05-17	2020-11-26	Xencor, Inc.	Protéines de fusion il-7-fc
JP7489407B2 (ja)	2019-05-21	2024-05-23	ノバルティスアーゲー	Ｃｄ１９結合分子及びその使用
CR20210622A (es)	2019-06-14	2022-06-27	Teneobio Inc	Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN112111012B (zh) *	2019-06-20	2023-07-04	成都恩沐生物科技有限公司	共价多特异性抗体
WO2021026387A2 (fr)	2019-08-06	2021-02-11	Xencor, Inc.	Anticorps bispécifiques de type igg hétérodimères
CN115916233A (zh)	2019-10-03	2023-04-04	Xencor股份有限公司	靶向IL-12异源二聚体Fc融合蛋白
TW202128757A (zh)	2019-10-11	2021-08-01	美商建南德克公司	具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
TW202146452A (zh)	2020-02-28	2021-12-16	瑞士商諾華公司	結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
TWI874613B (zh) *	2020-03-17	2025-03-01	美商西雅圖免疫公司	微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
WO2021222595A2 (fr) *	2020-04-30	2021-11-04	Virtuoso Binco, Inc.	Anticorps multispécifiques ciblant cd38 et epcam et leurs utilisations
US20230183381A1 (en) *	2020-05-12	2023-06-15	Virtuoso Binco, Inc.	Multispecific antibodies targeting cd38 and bcma and uses thereof
WO2021231969A1 (fr)	2020-05-14	2021-11-18	Xencor, Inc.	Anticorps hétérodimères se liant à msln et cd3
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
AU2021329378A1 (en)	2020-08-19	2023-03-23	Xencor, Inc.	Anti-CD28 compositions
US20230348596A1 (en)	2020-08-24	2023-11-02	Amgen Inc.	Pharmaceutical formulation
US20220135684A1 (en)	2020-10-14	2022-05-05	Xencor, Inc.	Bispecific antibodies that bind pd-l1 and cd28
US20250197519A1 (en)	2020-10-23	2025-06-19	Xencor, Inc.	Anti-cd20 antibodies and therapeutic uses thereof
US20220227867A1 (en)	2020-12-24	2022-07-21	Xencor, Inc.	ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
SI4284512T1 (sl)	2021-01-28	2025-06-30	Regeneron Pharmaceuticals, Inc.	Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
CA3212665A1 (fr)	2021-03-09	2022-09-15	Xencor, Inc.	Anticorps heterodimeriques se liant a cd3 et a cldn6
KR20230154311A (ko)	2021-03-10	2023-11-07	젠코어 인코포레이티드	Cd3 및 gpc3에 결합하는 이종이량체 항체
IL307468A (en) *	2021-04-05	2023-12-01	Cytovia Therapeutics Llc	Bispecific antibodies targeting NKP46 and CD38 and methods of using them
WO2022266219A1 (fr)	2021-06-15	2022-12-22	Xencor, Inc.	Anticorps hétérodimères se liant à la claudine 18.2 et à cd3
WO2023010021A1 (fr)	2021-07-27	2023-02-02	Xencor, Inc.	Protéines de fusion il-18-fc
US20250277051A1 (en) *	2021-08-02	2025-09-04	Hangzhou Unogen Biotech, Ltd	Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
CN115724985A (zh) *	2021-08-27	2023-03-03	三生国健药业（上海）股份有限公司	一种cdc平台抗体
EP4408889A1 (fr)	2021-09-27	2024-08-07	Xencor, Inc.	Compositions de domaine de liaison à l'antigène de maturation des lymphocytes b (bcma)
WO2023081915A1 (fr)	2021-11-08	2023-05-11	Xencor, Inc.	Il-8 en tant que biomarqueur prédictif et ses méthodes d'utilisation pour le traitement du cancer
WO2023086772A1 (fr)	2021-11-12	2023-05-19	Xencor, Inc.	Anticorps bispécifiques se liant à b7h3 et à nkg2d
CA3252619A1 (fr)	2022-02-23	2023-08-31	Xencor, Inc.	Anticorps anti-cd28 et anti-psma
US20240025968A1 (en)	2022-04-07	2024-01-25	Xencor, Inc.	LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
EP4507790A1 (fr)	2022-04-11	2025-02-19	Regeneron Pharmaceuticals, Inc.	Compositions et méthodes permettant la destruction de cellule tumorale universelle
JP2025512391A (ja)	2022-04-13	2025-04-17	ゼンコアインコーポレイテッド	Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体
CA3256382A1 (fr)	2022-04-26	2023-11-02	Amgen Inc.	Procédé de lyophilisation
US12083189B2 (en)	2022-04-29	2024-09-10	Tiba Biotech, Llc	Tail-conjugated RNAs
WO2024102636A1 (fr)	2022-11-07	2024-05-16	Xencor, Inc.	Anticorps bispécifiques qui se lient à b7h3 et mica/b
WO2024102645A1 (fr)	2022-11-07	2024-05-16	Xencor, Inc.	Traitement combiné comportant un anticorps bispécifique qui se lie à ctla4 et à pd1 contre le cancer de la prostate
US20240166705A1 (en)	2022-11-07	2024-05-23	Xencor, Inc.	Il18-fc fusion proteins
CN120857940A (zh)	2023-02-17	2025-10-28	瑞泽恩制药公司	对cd3/taa双特异性抗体有反应的诱导型nk细胞
AU2024260531A1 (en)	2023-04-28	2025-10-30	Xencor, Inc.	Orthogonal multimeric proteins
TW202525853A (zh)	2023-08-28	2025-07-01	美商山可爾股份有限公司	抗ｃｄ２０ｘ抗ｃｄ２８組合療法
WO2025085672A1 (fr)	2023-10-17	2025-04-24	Xencor, Inc.	Anticorps bispécifiques qui se lient à nkp46 et mica/b
WO2025085447A1 (fr)	2023-10-17	2025-04-24	Xencor, Inc.	Protéines de fusion il18-fc ciblant pd-1
US12134635B1 (en)	2023-12-29	2024-11-05	Sonnet BioTherapeutics, Inc.	Interleukin 18 (IL-18) variants and fusion proteins comprising same
US20250361311A1 (en)	2024-05-24	2025-11-27	Xencor, Inc.	Anti-tnf-like ligand 1a (tl1a) antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012131555A2 (fr) *	2011-03-25	2012-10-04	Glenmark Pharmaceuticals S.A.	Immunoglobulines hétéro-dimériques
US20130209355A1 (en) *	2010-06-09	2013-08-15	Genmab A/S	Antibodies against human cd38
WO2014110601A1 (fr) *	2013-01-14	2014-07-17	Xencor, Inc.	Nouvelles protéines hétérodimères
US20140294833A1 (en) *	2013-01-14	2014-10-02	Xencor, Inc.	Novel heterodimeric proteins
WO2016086189A2 (fr) *	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimériques se liant à l'antigène cd3 et à un antigène tumoral
WO2016086196A2 (fr) *	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38

Family Cites Families (373)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CA1023287A (fr)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Procede de fixation d'une proteine sur un substrat
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (fr)	1977-02-17	1981-01-20	Hideo Hirohara	Traduction non-disponible
US4169888A (en)	1977-10-17	1979-10-02	The Upjohn Company	Composition of matter and process
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
EP0028683A1 (fr)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotique C-15003 PHO et sa préparation
US4364935A (en)	1979-12-04	1982-12-21	Ortho Pharmaceutical Corporation	Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
WO1982001188A1 (fr)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
EP0271581B1 (fr)	1986-04-17	1993-01-13	Kyowa Hakko Kogyo Co., Ltd.	Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4880935A (en)	1986-07-11	1989-11-14	Icrf (Patents) Limited	Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en)	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
FI102355B1 (fi)	1988-02-11	1998-11-30	Bristol Myers Squibb Co	Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5084468A (en)	1988-08-11	1992-01-28	Kyowa Hakko Kogyo Co., Ltd.	Dc-88a derivatives
JP2598116B2 (ja)	1988-12-28	1997-04-09	協和醗酵工業株式会社	新規物質ｄｃ１１３
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JP2510335B2 (ja)	1989-07-03	1996-06-26	協和醗酵工業株式会社	Ｄｃ―８８ａ誘導体
US5187186A (en)	1989-07-03	1993-02-16	Kyowa Hakko Kogyo Co., Ltd.	Pyrroloindole derivatives
CA2026147C (fr)	1989-10-25	2006-02-07	Ravi J. Chari	Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
IE911537A1 (en)	1990-05-07	1991-11-20	Scripps Clinic Res	Intermediates in the formation of the calicheamicin and¹esperamicin oligosaccharides
US5968509A (en)	1990-10-05	1999-10-19	Btp International Limited	Antibodies with binding affinity for the CD3 antigen
CZ282603B6 (cs)	1991-03-06	1997-08-13	Merck Patent Gesellschaft Mit Beschränkter Haftun G	Humanizované a chimerické monoklonální protilátky
CA2103059C (fr)	1991-06-14	2005-03-22	Paul J. Carter	Methode de production d'anticorps humanises
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
US5622929A (en)	1992-01-23	1997-04-22	Bristol-Myers Squibb Company	Thioether conjugates
GB9206422D0 (en)	1992-03-24	1992-05-06	Bolt Sarah L	Antibody preparation
DE69231123T2 (de)	1992-03-25	2001-02-15	Immunogen Inc	Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6329507B1 (en)	1992-08-21	2001-12-11	The Dow Chemical Company	Dimer and multimer forms of single chain polypeptides
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
EP0672142B1 (fr)	1992-12-04	2001-02-28	Medical Research Council	Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
SG55079A1 (en)	1992-12-11	1998-12-21	Dow Chemical Co	Multivalent single chain antibodies
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
ES2233928T3 (es)	1993-10-01	2005-06-16	Teikoku Hormone Mfg. Co., Ltd.	Derivados de dolastatina.
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
CA2165819C (fr)	1994-04-22	2005-12-27	Nobuyoshi Amishiro	Derives de dc-89
JPH07309761A (ja)	1994-05-20	1995-11-28	Kyowa Hakko Kogyo Co Ltd	デュオカルマイシン誘導体の安定化法
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5945311A (en)	1994-06-03	1999-08-31	GSF--Forschungszentrumfur Umweltund Gesundheit	Method for producing heterologous bi-specific antibodies
US5550246A (en)	1994-09-07	1996-08-27	The Scripps Research Institute	Calicheamicin mimics
US5541087A (en)	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US5663149A (en)	1994-12-13	1997-09-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1996040210A1 (fr)	1995-06-07	1996-12-19	Imclone Systems Incorporated	Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7696338B2 (en)	1995-10-30	2010-04-13	The United States Of America As Represented By The Department Of Health And Human Services	Immunotoxin fusion proteins and means for expression thereof
DE69626849T2 (de)	1995-12-22	2003-12-24	Bristol-Myers Squibb Co., Princeton	Verzweigte hydrazongruppen enthaltende kuppler
WO1997024373A1 (fr)	1995-12-29	1997-07-10	Medvet Science Pty. Limited	Antagonistes d'anticorps monoclonaux diriges contre des facteurs de croissance hematopoietiques
AUPN999096A0 (en)	1996-05-22	1996-06-13	Northstar Biologicals Pty Ltd	Peptides, antibodies, vaccines & uses thereof
EP0915987A2 (fr)	1997-04-21	1999-05-19	Donlar Corporation	ACIDE POLY-$g(a)-L-ASPARTIQUE, ACIDE-POLY-$g(a)-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
DK0979281T3 (da)	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ES2234241T3 (es)	1998-01-23	2005-06-16	Vlaams Interuniversitair Instituut Voor Biotechnologie	Derivados de anticuerpo de multiples fines.
PT1071700E (pt)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO1999054440A1 (fr)	1998-04-21	1999-10-28	Micromet Gesellschaft Für Biomedizinische Forschung Mbh	Polypeptides specifiques a cd19 et cd3 et leurs utilisations
US6455677B1 (en)	1998-04-30	2002-09-24	Boehringer Ingelheim International Gmbh	FAPα-specific antibody with improved producibility
JP4113670B2 (ja)	1998-06-22	2008-07-09	イムノメディクス，インコーポレイテッド	プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
GB9815909D0 (en)	1998-07-21	1998-09-16	Btg Int Ltd	Antibody preparation
US6723538B2 (en)	1999-03-11	2004-04-20	Micromet Ag	Bispecific antibody and chemokine receptor constructs
WO2000061739A1 (fr)	1999-04-09	2000-10-19	Kyowa Hakko Kogyo Co., Ltd.	Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6939545B2 (en)	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
WO2001024763A2 (fr)	1999-10-01	2001-04-12	Immunogen, Inc.	Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US7303749B1 (en)	1999-10-01	2007-12-04	Immunogen Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7504256B1 (en)	1999-10-19	2009-03-17	Kyowa Hakko Kogyo Co., Ltd.	Process for producing polypeptide
US6716410B1 (en)	1999-10-26	2004-04-06	The Regents Of The University Of California	Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
EP1266009B1 (fr)	2000-02-25	2008-12-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	SCFV ANTI-EGFRvIII POSSEDANT UNE CYTOTOXICITE ET UN RENDEMENT AMELIORES, IMMUNOTOXINES A BASE DE CES SCFV ET PROCEDE D'UTILISATION ASSOCIE
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
US20010035606A1 (en)	2000-03-28	2001-11-01	Schoen Alan H.	Set of blocks for packing a cube
MXPA02010787A (es)	2000-05-03	2003-07-14	Amgen Inc	Peptidos modificados como agentes terapeuticos.
ES2259030T3 (es)	2000-05-19	2006-09-16	Scancell Limited	Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
EP1299419A2 (fr)	2000-05-24	2003-04-09	Imclone Systems, Inc.	Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
CA2417185A1 (fr)	2000-07-25	2002-01-31	Shui-On Leung	Proteine de liaison cible multivalente
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
DE10043437A1 (de)	2000-09-04	2002-03-28	Horst Lindhofer	Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
EP1333032A4 (fr)	2000-10-06	2005-03-16	Kyowa Hakko Kogyo Kk	Procede de purification d'un anticorps
MXPA03002974A (es)	2000-10-06	2004-05-05	Kyowa Hakko Kogyo Kk	Celulas que producen composiciones de anticuerpo.
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US20020147312A1 (en)	2001-02-02	2002-10-10	O'keefe Theresa	Hybrid antibodies and uses thereof
EP1243276A1 (fr)	2001-03-23	2002-09-25	Franciscus Marinus Hendrikus De Groot	Prodrogues activables à séparateurs allongés et multiples
AU2002307037B2 (en)	2001-04-02	2008-08-07	Biogen Idec Inc.	Recombinant antibodies coexpressed with GnTIII
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR20030033007A (ko)	2001-05-31	2003-04-26	코울터 파머수티컬, 인코포레이티드	세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
RU2335507C2 (ru)	2001-06-13	2008-10-10	Генмаб А/С	Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US20040242851A1 (en)	2001-06-26	2004-12-02	Zhenping Zhu	Bispecific antibodies that bind to vegf receptors
US6513428B1 (en)	2001-07-23	2003-02-04	Heidelberger Druckmaschinen Ag	Device and method for attaching a printing web to a webbing sail and device and method for webbing-up a printing machine
NZ532526A (en)	2001-10-25	2007-01-26	Genentech Inc	Compositions comprising a glycoprotein having a Fc region
EP1490677A4 (fr)	2002-02-27	2006-01-18	California Inst Of Techn	Procede informatique de conception d'enzymes pour l'incorporation d'analogues d'acides amines dans des proteines
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7657380B2 (en)	2003-12-04	2010-02-02	Xencor, Inc.	Methods of generating variant antibodies with increased host string content
US20080219974A1 (en)	2002-03-01	2008-09-11	Bernett Matthew J	Optimized antibodies that target hm1.24
US7332580B2 (en)	2002-04-05	2008-02-19	The Regents Of The University Of California	Bispecific single chain Fv antibody molecules and methods of use thereof
EP2316921B1 (fr)	2002-05-24	2014-05-14	Merck Sharp & Dohme Corp.	Anticorps anti-IGFR humain neutralisant
JP4741838B2 (ja)	2002-07-31	2011-08-10	シアトルジェネティクス，インコーポレーテッド	癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
US8946387B2 (en)	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
EP1391213A1 (fr)	2002-08-21	2004-02-25	Boehringer Ingelheim International GmbH	Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
US20060235208A1 (en)	2002-09-27	2006-10-19	Xencor, Inc.	Fc variants with optimized properties
DE10246870B3 (de)	2002-10-08	2004-04-29	Renk Aktiengesellschaft	Elektro-Hydrodynamische Überlagerungslenkung
US7820166B2 (en)	2002-10-11	2010-10-26	Micromet Ag	Potent T cell modulating molecules
JP2006507322A (ja)	2002-11-14	2006-03-02	シンタルガ・ビーブイ	多重自己脱離放出スペーサーとして構築されたプロドラッグ
NZ540555A (en)	2002-11-15	2008-04-30	Genmab As	Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en)	2003-03-31	2009-10-27	Xencor, Inc.	Methods for rational pegylation of proteins
EP3524611B1 (fr)	2003-05-20	2020-12-30	ImmunoGen, Inc.	Agents cytotoxiques améliorés contenant de nouveaux maytansinoïdes
US7276497B2 (en)	2003-05-20	2007-10-02	Immunogen Inc.	Cytotoxic agents comprising new maytansinoids
AU2004242847B2 (en)	2003-05-31	2011-06-09	Amgen Research (Munich) Gmbh	Pharmaceutical composition comprising a bispecific antibody for EpCAM
RU2005141512A (ru)	2003-05-31	2007-07-20	Микромет Аг (De)	Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
US7888134B2 (en)	2003-06-05	2011-02-15	Oakland University	Immunosensors: scFv-linker design for surface immobilization
US20060134105A1 (en)	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
US20150071948A1 (en)	2003-09-26	2015-03-12	Gregory Alan Lazar	Novel immunoglobulin variants
ES2737837T3 (es)	2003-10-09	2020-01-16	Ambrx Inc	Derivados poliméricos
US20050176028A1 (en)	2003-10-16	2005-08-11	Robert Hofmeister	Deimmunized binding molecules to CD3
CN104998273A (zh)	2003-11-06	2015-10-28	西雅图基因公司	能够与配体偶联的单甲基缬氨酸化合物
EP1701979A2 (fr)	2003-12-03	2006-09-20	Xencor, Inc.	Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
EP2275448A3 (fr)	2003-12-19	2013-02-06	Genentech, Inc.	Fragments d'anticorps monovalent et leur utilisation thérapeutique
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
NZ548255A (en)	2004-02-02	2010-10-29	Ambrx Inc	Modified human interferon polypeptides and their uses
JP2008504013A (ja) *	2004-02-06	2008-02-14	モルフォシス・アクチェンゲゼルシャフト	抗ｃｄ３８ヒト抗体及びその用途
WO2005112919A2 (fr)	2004-05-19	2005-12-01	Medarex, Inc.	Bras de liaison chimiques et conjugues associes
US7691962B2 (en)	2004-05-19	2010-04-06	Medarex, Inc.	Chemical linkers and conjugates thereof
UA94211C2 (ru) *	2004-06-03	2011-04-26	Новиммюн С.А.	Выделенное полностью человеческое моноклональное cd3 антитело
WO2005118635A2 (fr)	2004-06-03	2005-12-15	Novimmune S.A.	Anticorps anti-cd3 et leurs methodes d'utilisation
WO2006004910A2 (fr)	2004-06-28	2006-01-12	Transtarget Inc.	Anticorps bispecifiques ameliores
WO2006020258A2 (fr)	2004-07-17	2006-02-23	Imclone Systems Incorporated	Nouveau anticorps bispecifique tetravalent
ZA200701783B (en)	2004-09-02	2009-10-28	Genentech Inc	Anti-Fc-gamma RIIB receptor antibody and uses therefor
EP3088004B1 (fr)	2004-09-23	2018-03-28	Genentech, Inc.	Anticorps et conjugués modifiés au niveau des cystéines
DK1797127T3 (en)	2004-09-24	2017-10-02	Amgen Inc	Modified Fc molecules
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8066989B2 (en)	2004-11-30	2011-11-29	Trion Pharma Gmbh	Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
ATE414718T1 (de)	2005-01-05	2008-12-15	F Star Biotech Forsch & Entw	Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
US8716451B2 (en)	2005-01-12	2014-05-06	Kyowa Hakko Kirin Co., Ltd	Stabilized human IgG2 and IgG3 antibodies
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
US7714016B2 (en)	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
US9284375B2 (en)	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
RS52861B (sr)	2005-06-07	2013-12-31	Esbatech - A Novartis Company Llc	Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
US8741566B2 (en)	2005-07-01	2014-06-03	Dako Denmark A/S	Immunohistochemistry and in situ hybridization detection method
EP1899477A4 (fr)	2005-07-01	2010-01-20	Medimmune Inc	Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
PT1912675E (pt)	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
US20080213273A1 (en)	2005-07-25	2008-09-04	Trubion Pharmaceuticals Inc.	Single dose use of CD20-specific binding molecules
CA2617907A1 (fr)	2005-08-05	2007-02-15	Syntarga B.V.	Bras de liaison detachables contenant du triazole et conjugues de ceux-ci
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
WO2007033230A2 (fr)	2005-09-12	2007-03-22	Novimmune S.A.	Formulations d'anticorps anti-cd3
EP1931709B1 (fr)	2005-10-03	2016-12-07	Xencor, Inc.	Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
EP3770174A1 (fr)	2005-10-11	2021-01-27	Amgen Research (Munich) GmbH	Compositions comprenant des anticorps spécifiques aux espèces croisées et leurs utilisations
HUE035250T2 (hu)	2005-10-12	2018-05-02	Morphosys Ag	Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
CN101331223A (zh)	2005-10-14	2008-12-24	米迪缪尼有限公司	细胞展示抗体文库
WO2007047829A2 (fr)	2005-10-19	2007-04-26	Laboratoires Serono S.A.	Nouvelles protéines hétérodimères et utilisations de celles-ci
EP1777294A1 (fr)	2005-10-20	2007-04-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
TW200732350A (en)	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
CA2627190A1 (fr)	2005-11-10	2007-05-24	Medarex, Inc.	Composes et conjugues cytotoxiques
US7820165B2 (en)	2005-11-21	2010-10-26	Merck Serono, S.A.	Compositions and methods of producing hybrid antigen binding molecules and uses thereof
KR20080090441A (ko)	2005-12-21	2008-10-08	메디뮨 엘엘씨	Ｅｐｈａ２ｂｉｔｅ 분자 및 이의 용도
WO2007084342A2 (fr)	2006-01-13	2007-07-26	The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Il-15 et il-15r-alpha améliorées aux fins d'expression dans des cellules mammaliennes
KR20080114709A (ko)	2006-02-02	2008-12-31	신타가 비.브이.	수용성 ｃｃ-1065 유사체 및 그들의 결합체
EP1820513A1 (fr)	2006-02-15	2007-08-22	Trion Pharma Gmbh	Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
EP1829895A1 (fr)	2006-03-03	2007-09-05	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Molécule bispécifique anti-TLR9 et anti-CD32 contenant un épitope de lymphocyte T pour le traitement des allergies
SG170750A1 (en)	2006-03-17	2011-05-30	Biogen Idec Inc	Stabilized polypeptide compositions
ES2395969T3 (es)	2006-03-24	2013-02-18	Merck Patent Gmbh	Dominios de proteínas heterodiméricas genéticamente modificados
EP3056568B1 (fr)	2006-03-31	2021-09-15	Chugai Seiyaku Kabushiki Kaisha	Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
JP5144499B2 (ja)	2006-03-31	2013-02-13	中外製薬株式会社	二重特異性抗体を精製するための抗体改変方法
EP2007423A2 (fr)	2006-04-05	2008-12-31	Pfizer Products Incorporated	Polythérapie à base d'un anticorps anti-ctla4
WO2007147901A1 (fr)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production d'anticorps bispécifiques
AT503902B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von immunglobulinen
AT503861B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
CN101548034B (zh)	2006-10-02	2013-11-13	航道生物技术有限责任公司	多样性合成肽和多肽文库的设计和构建
PL2383289T3 (pl)	2006-10-16	2015-03-31	Salk Inst Biological Studies	Antagoniści somatostatyny selektywni względem receptora (SSTR2)
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
US7862825B2 (en)	2007-02-21	2011-01-04	Mladen Vranic	Method of controlling tight blood glucose by somatostatin receptor antagonists
CA2680237C (fr)	2007-03-27	2018-11-06	Sea Lane Biotechnologies, Llc	Constructions et bibliotheques comprenant des sequences de chaines legeres de substitution d'anticorps
EP1975178A1 (fr)	2007-03-30	2008-10-01	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Anticorps modulaire transcytotique
WO2008119566A2 (fr)	2007-04-03	2008-10-09	Micromet Ag	Éléments de liaison bispécifiques spécifiques d'espèces croisées
PT2520590T (pt)	2007-04-03	2018-11-14	Amgen Res Munich Gmbh	Domínio de ligação específico de espécies cruzadas
WO2008124858A2 (fr)	2007-04-11	2008-10-23	F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H.	Récepteur ciblé
KR20100021601A (ko)	2007-05-14	2010-02-25	바이오겐 아이덱 엠에이 인코포레이티드	단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
EP3392273A1 (fr)	2007-05-30	2018-10-24	Xencor, Inc.	Procédés et compositions pour inhiber des cellules exprimant cd32b
CA2688275A1 (fr)	2007-05-31	2008-12-04	Genmab A/S	Anticorps igg4 stables
CA2691322A1 (fr)	2007-06-12	2008-12-24	Wyeth	Compositions therapeutiques anti-cd20 et procedes correspondants
HUE066143T2 (hu)	2007-06-26	2024-07-28	F Star Therapeutics Ltd	Kötõágensek megjelenítése
WO2009017823A2 (fr)	2007-08-01	2009-02-05	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health	Immunotoxine de la toxine diphtérique d'un dianticorps de repliement et ses procédés d'utilisation
US8680293B2 (en)	2007-08-01	2014-03-25	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
CA2697922A1 (fr)	2007-08-28	2009-03-12	Biogen Idec Ma Inc.	Compositions qui se lient a de multiples epitopes de igf-1r
EP2033657A1 (fr)	2007-09-04	2009-03-11	Trion Pharma Gmbh	Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
MX2010002683A (es)	2007-09-14	2010-03-26	Amgen Inc	Poblaciones de anticuerpos homogeneos.
CA2700714C (fr)	2007-09-26	2018-09-11	Ucb Pharma S.A.	Fusions d'anticorps a double specificite
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
RU2526512C2 (ru)	2007-09-26	2014-08-20	Чугаи Сейяку Кабусики Кайся	Модифицированная константная область антитела
HRP20150279T1 (hr)	2007-12-26	2015-05-08	Xencor, Inc.	Fc inaäśice s promijenjenim vezanjem na fcrn
AU2009204501B2 (en)	2008-01-07	2015-02-12	Amgen Inc.	Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009106096A1 (fr)	2008-02-27	2009-09-03	Fresenius Biotech Gmbh	Traitement de tumeurs résistantes par des anticorps trifonctionnels
RS51975B (sr)	2008-04-11	2012-02-29	Emergent Product Development Seattle Llc.	Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
WO2009129538A2 (fr)	2008-04-18	2009-10-22	Xencor, Inc.	Anticorps monoclonaux d’équivalent humain conçus à partir de régions variables non humaines
CA2723197C (fr)	2008-05-02	2017-09-19	Seattle Genetics, Inc.	Procede et compositions pour preparer des anticorps et des derives d'anticorps avec une fucosylation centrale reduite
BRPI0913406A2 (pt)	2008-06-03	2018-01-09	Abbott Lab	imunoglobulinas de domínio variável duplo e usos das mesmas
WO2010028796A1 (fr)	2008-09-10	2010-03-18	F. Hoffmann-La Roche Ag	Anticorps hexavalents trispécifiques
EP3190128B1 (fr)	2008-09-17	2018-11-14	Xencor, Inc.	Compositions et méthodes de traitement de troubles induits par ige
US20170247470A9 (en)	2008-09-17	2017-08-31	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
MX2011003133A (es)	2008-09-26	2011-04-21	Roche Glycart Ag	Anticuerpos biespecificos anti-egfr/anti-igf-1r.
CA2738566C (fr)	2008-10-01	2024-04-30	Micromet Ag	Anticorps monocatenaires bispecifiques specifiques d'antigenes cibles de masse moleculaire elevee
EP2352765B1 (fr)	2008-10-01	2018-01-03	Amgen Research (Munich) GmbH	Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
BRPI0919840B1 (pt)	2008-10-01	2023-02-28	Amgen Research (Munich) Gmbh	Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
DK2356153T3 (en)	2008-10-01	2016-07-04	Amgen Res Munich Gmbh	Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
NZ603623A (en)	2008-10-10	2014-05-30	Emergent Product Dev Seattle	Tcr complex immunotherapeutics
JP5677970B2 (ja)	2008-11-03	2015-02-25	シンタルガ・ビーブイ	新規ｃｃ−１０６５類似体およびその複合体
CA2750533A1 (fr)	2009-01-23	2010-07-29	Biogen Idec Ma Inc.	Polypeptides fc stabilises avec une fonction effectrice reduite et procedes d'utilisation
SG174258A1 (en)	2009-03-06	2011-10-28	Genentech Inc	Antibody formulation
EP2233500A1 (fr)	2009-03-20	2010-09-29	LFB Biotechnologies	Variantes Fc optimisées
CN102369215B (zh)	2009-04-02	2015-01-21	罗切格利卡特公司	包含全长抗体和单链Fab片段的多特异性抗体
SG175078A1 (en)	2009-04-07	2011-11-28	Roche Glycart Ag	Bispecific anti-erbb-1/anti-c-met antibodies
SI2417156T1 (sl)	2009-04-07	2015-06-30	Roche Glycart Ag	Trivalentna, bispecifiäśna protitelesa
CA2757531A1 (fr)	2009-04-07	2010-10-14	Roche Glycart Ag	Anticorps anti-erbb-3/anti-c-met bispecifiques
EP2241576A1 (fr)	2009-04-17	2010-10-20	Trion Pharma Gmbh	Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
CN102448985B (zh)	2009-05-27	2015-08-05	霍夫曼-拉罗奇有限公司	三或四特异性抗体
BRPI1015916A2 (pt)	2009-06-26	2015-09-01	Sea Lane Biotechnologies Llc	Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc
ES2865648T3 (es)	2009-06-26	2021-10-15	Regeneron Pharma	Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
EP2451840B1 (fr)	2009-07-08	2018-12-26	Amgen Inc.	Conception de molécules fc d'anticorps exemptes d'agrégation et stables par ingénierie de l'interface du domaine ch3
WO2011028952A1 (fr)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
DE102009045006A1 (de)	2009-09-25	2011-04-14	Technische Universität Dresden	Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
SI2493503T2 (sl)	2009-10-27	2021-04-30	Amgen Research (Munich) Gmbh	Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa
JP2013511281A (ja)	2009-11-23	2013-04-04	アムジェンインコーポレイテッド	単量体抗体Ｆｃ
JP2013512251A (ja)	2009-11-24	2013-04-11	アンプリミューン、インコーポレーテッド	Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
ES2609043T3 (es)	2009-11-30	2017-04-18	Janssen Biotech, Inc.	Anticuerpos mutantes Fc con funciones de efecto abladas
US10817851B2 (en)	2009-12-23	2020-10-27	Aristocrat Technologies Australia Pty Limited	System and method for cashless gaming
ES2777901T3 (es)	2009-12-25	2020-08-06	Chugai Pharmaceutical Co Ltd	Método de modificación de polipéptidos para purificar multímeros polipeptídicos
US20130129723A1 (en)	2009-12-29	2013-05-23	Emergent Product Development Seattle, Llc	Heterodimer Binding Proteins and Uses Thereof
PT2519543T (pt)	2009-12-29	2016-10-07	Emergent Product Dev Seattle	Proteínas de ligação de heterodímero e suas utilizações
US20110189178A1 (en)	2010-02-04	2011-08-04	Xencor, Inc.	Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
EP2552957A4 (fr)	2010-03-29	2013-11-20	Zymeworks Inc	Anticorps présentant une fonction effectrice améliorée ou supprimée
TWI653333B (zh)	2010-04-01	2019-03-11	安進研究（慕尼黑）有限責任公司	跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9150663B2 (en)	2010-04-20	2015-10-06	Genmab A/S	Heterodimeric antibody Fc-containing proteins and methods for production thereof
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
WO2011143545A1 (fr)	2010-05-14	2011-11-17	Rinat Neuroscience Corporation	Protéines hétérodimériques et leurs procédés de production et de purification
CN103052649B (zh)	2010-07-29	2015-12-16	Xencor公司	具有修改的等电点的抗体
CN103154025B (zh)	2010-08-02	2015-07-01	宏观基因有限公司	共价双抗体及其用途
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
WO2012032080A1 (fr)	2010-09-07	2012-03-15	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H	Fc humain stabilisé
AU2011325833C1 (en)	2010-11-05	2017-07-13	Zymeworks Bc Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
SMT201700250T1 (it)	2010-11-10	2017-07-18	Amgen Res Munich Gmbh	Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
EP2638072A4 (fr)	2010-11-12	2014-05-07	Univ Rockefeller	Protéines de fusion pour une thérapie contre le vih
CN105440123B (zh)	2011-02-10	2020-10-09	罗切格利卡特公司	突变体白介素-2多肽
JP6101638B2 (ja)	2011-03-03	2017-03-22	ザイムワークス，インコーポレイテッド	多価ヘテロマルチマー足場設計及び構築物
CA2829628A1 (fr)	2011-03-11	2012-09-20	Amgen Inc.	Procede d'analyse mutationnelle correlee pour ameliorer des anticorps therapeutiques
JP5972915B2 (ja)	2011-03-16	2016-08-17	アムジエン・インコーポレーテツド	Ｆｃ変異体
TWI671315B (zh)	2011-03-28	2019-09-11	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
SI2691417T2 (sl)	2011-03-29	2025-05-30	Roche Glycart Ag	FC variante protitelesa
EP2701741B1 (fr)	2011-04-28	2020-06-10	Amgen Research (Munich) GmbH	Régime posologique pour l'administration d'un anticorps bispécifique cd19xcd3 à des patients à risque d'éventuels effets indésirables
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
BR112013029893A2 (pt)	2011-05-21	2017-05-30	Macrogenics Inc	molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
CN103582650A (zh)	2011-05-25	2014-02-12	默沙东公司	用于制备具有改善性质的含Fc多肽的方法
WO2013006544A1 (fr)	2011-07-06	2013-01-10	Medimmune, Llc	Procédé de préparation de polypeptides multimères
WO2013016714A1 (fr)	2011-07-28	2013-01-31	Sea Lane Biotechnologies	Protéines se liant à sur dirigées contre erbb3
JP6015448B2 (ja)	2011-08-04	2016-10-26	東レ株式会社	癌の治療及び／又は予防用医薬組成物
WO2013022855A1 (fr)	2011-08-05	2013-02-14	Xencor, Inc.	Anticorps avec points isoélectriques modifiés et immunofiltration
JP6244301B2 (ja)	2011-08-18	2017-12-06	アフィニティバイオサイエンスピーティーワイリミテッド	可溶性ポリペプチド
NO2748201T3 (fr)	2011-08-23	2018-05-12
EP2748197A2 (fr)	2011-08-26	2014-07-02	Merrimack Pharmaceuticals, Inc.	Anticorps bispécifiques à fc en tandem
WO2013047748A1 (fr)	2011-09-30	2013-04-04	中外製薬株式会社	Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
DK2766392T3 (da)	2011-10-10	2019-10-07	Xencor Inc	Fremgangsmåde til oprensning af antistoffer
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN109608543A (zh)	2011-10-20	2019-04-12	艾斯巴技术-诺华有限责任公司	稳定的多抗原结合抗体
EA034989B1 (ru)	2011-10-28	2020-04-15	Тева Фармасьютикал Австралия Пти Лтд	Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
EP2787078B1 (fr)	2011-10-31	2019-05-22	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à un antigène à conjugaison régulée entre une chaîne lourde et une chaîne légère
WO2013063702A1 (fr)	2011-11-04	2013-05-10	Zymeworks Inc.	Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
EP2776061B1 (fr)	2011-11-07	2019-08-14	MedImmune, LLC	Protéines de liaison multispécifiques et multivalentes et leurs utilisations
US9975956B2 (en)	2011-12-22	2018-05-22	I2 Pharmaceuticals, Inc.	Surrogate binding proteins which bind DR4 and/or DR5
KR20220136441A (ko)	2012-02-24	2022-10-07	추가이 세이야쿠 가부시키가이샤	ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
PT2838917T (pt)	2012-04-20	2019-09-12	Merus Nv	Métodos e meios para a produção de moléculas similares a ig heterodiméricas
NZ701821A (en)	2012-04-30	2016-06-24	Biocon Ltd	Targeted/immunomodulatory fusion proteins and methods for making same
DK2857419T3 (da)	2012-05-30	2021-03-29	Chugai Pharmaceutical Co Ltd	Antigen-bindende molekyle til eliminering af aggregerede antigener
WO2014004586A1 (fr)	2012-06-25	2014-01-03	Zymeworks Inc.	Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
AU2013289883B2 (en)	2012-07-13	2018-11-01	Zymeworks Bc Inc.	Bispecific asymmetric heterodimers comprising anti-CD3 constructs
CN104640561A (zh)	2012-07-23	2015-05-20	酵活有限公司	包含轻链和重链的选择性配对的免疫球蛋白构建体
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IN2015MN00139A (fr)	2012-09-25	2015-10-16	Glenmark Pharmaceuticals Sa
EP2904016B1 (fr)	2012-10-08	2018-11-14	Roche Glycart AG	Anticorps exempts de fc comprenant deux fragments fab et procédés d'utilisation
JP6571527B2 (ja)	2012-11-21	2019-09-04	ウーハンワイゼットワイバイオファルマカンパニーリミテッドＷｕｈａｎＹｚｙＢｉｏｐｈａｒｍａＣｏ．，Ｌｔｄ．	二重特異性抗体
CN104955953B (zh)	2012-11-27	2019-04-26	亚洲大学校产学协力团	高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对，其制备方法及用途
US20140377269A1 (en)	2012-12-19	2014-12-25	Adimab, Llc	Multivalent antibody analogs, and methods of their preparation and use
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US9738722B2 (en)	2013-01-15	2017-08-22	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
CN103943548A (zh)	2013-01-23	2014-07-23	无锡华润上华半导体有限公司	分立式场氧结构的半导体器件的制造方法
AU2014249243C1 (en)	2013-03-13	2019-08-08	Imaginab, Inc.	Antigen binding constructs to CD8
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10544187B2 (en)	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
WO2014145806A2 (fr)	2013-03-15	2014-09-18	Xencor, Inc.	Protéines hétérodimériques
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US20160145355A1 (en)	2013-06-24	2016-05-26	Biomed Valley Discoveries, Inc.	Bispecific antibodies
GB201311487D0 (en)	2013-06-27	2013-08-14	Alligator Bioscience Ab	Bispecific molecules
PL3444271T3 (pl)	2013-08-08	2022-03-07	Cytune Pharma	Modulokiny oparte na il-15 i domenie sushi il-15ralfa
EP2839842A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
MY176522A (en)	2013-11-04	2020-08-13	Ichnos Sciences SA	Production of t cell retargeting hetero-dimeric immunoglobulins
CA2933881A1 (fr)	2013-12-17	2015-06-25	Genentech, Inc.	Methodes de traitement du cancer a l'aide d'antagonistes se liant a l'axe pd-1 et d'anticorps anti-cd20
BR112016013963A2 (pt)	2013-12-17	2017-10-10	Genentech Inc	terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
PE20210107A1 (es)	2013-12-17	2021-01-19	Genentech Inc	Anticuerpos anti-cd3 y metodos de uso
DK3089994T3 (da)	2013-12-30	2022-07-04	Epimab Biotherapeutics Inc	Fabs-in-tandem-immunglobulin og anvendelser deraf
MX374391B (es)	2014-01-08	2025-03-06	Shanghai hengrui pharmaceutical co ltd	Proteina heterodimérica il-15 y usos de la misma.
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
EP3122781B1 (fr)	2014-03-28	2020-01-01	Xencor, Inc.	Anticorps bispécifiques se liant à cd38 et cd3
CN107073090A (zh)	2014-04-30	2017-08-18	哈佛学院董事会	结合的疫苗装置和杀死癌细胞的方法
SG10201913324PA (en)	2014-05-29	2020-03-30	Macrogenics Inc	Tri-specific binding molecules and methods of use thereof
AU2015292326A1 (en)	2014-07-24	2017-02-23	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
ES2791248T3 (es)	2014-08-19	2020-11-03	Novartis Ag	Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
SG11201701867SA (en)	2014-09-09	2017-04-27	Janssen Biotech Inc	Combination therapies with anti-cd38 antibodies
MA40894A (fr)	2014-11-04	2017-09-12	Glenmark Pharmaceuticals Sa	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
DK4141032T3 (da)	2014-11-20	2024-08-05	Hoffmann La Roche	Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
WO2016086186A2 (fr)	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimères à liaison à cd8
US10259887B2 (en) *	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (fr)	2014-12-22	2017-11-01	Xencor, Inc.	Anticorps trispécifiques
CN117843799A (zh)	2015-01-08	2024-04-09	生物技术公司	激动性tnf受体结合剂
AU2016206707A1 (en)	2015-01-14	2017-08-10	Compass Therapeutics Llc	Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
CA2984134A1 (fr)	2015-05-08	2016-11-17	Xencor, Inc.	Anticorps heterodimeriques se liant aux antigenes cd3 et tumoraux
EP3313441B1 (fr)	2015-06-24	2024-02-21	Janssen Biotech, Inc.	Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
SI3328419T1 (sl)	2015-07-30	2021-11-30	Macrogenics, Inc.	PD-1-vezavne molekule in postopki uporabe le-teh
US20180305465A1 (en) *	2015-11-25	2018-10-25	Amgen Inc.	Heterodimeric antibodies that bind cd3 and cd38
WO2017100372A1 (fr)	2015-12-07	2017-06-15	Xencor, Inc.	Anticorps hétérodimèes se liant à cd3 et psma
BR112018012801B1 (pt)	2015-12-22	2024-03-12	Regeneron Pharmaceuticals, Inc	Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
EP3464365A1 (fr)	2016-06-01	2019-04-10	Xencor, Inc.	Anticorps bispécifiques qui lient cd123 et cd3
EP3464370A1 (fr)	2016-06-01	2019-04-10	Xencor, Inc.	Anticorps bispécifiques qui se lient à cd20 et cd3 destinés à être utilisés dans le traitement d'un lymphome
EP3252078A1 (fr)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
EP3463464A4 (fr)	2016-06-07	2020-07-01	MacroGenics, Inc.	Traitement d'association
WO2017218707A2 (fr)	2016-06-14	2017-12-21	Xencor, Inc.	Anticorps inhibiteurs de points de contrôle bispécifiques
US10316088B2 (en)	2016-06-28	2019-06-11	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
TW201815825A (zh)	2016-07-21	2018-05-01	財團法人生物技術開發中心	經修飾之抗原結合fab片段及包含其之抗原結合分子
JP2019532621A (ja)	2016-08-29	2019-11-14	サイオクサスセラピューティクスリミテッド	二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MA46534A (fr)	2016-10-14	2019-08-21	Xencor Inc	Protéines de fusion fc hétérodimères il15/il15r
US11392902B2 (en)	2017-06-06	2022-07-19	United Parcel Service Of America, Inc.	Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
WO2019050521A1 (fr)	2017-09-07	2019-03-14	Macrogenics, Inc.	Schémas posologiques de diacorps bispécifiques cd123 x cd3 dans le traitement de malignités hématologiques
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en)	2017-11-08	2020-05-28	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2021026387A2 (fr)	2019-08-06	2021-02-11	Xencor, Inc.	Anticorps bispécifiques de type igg hétérodimères

2015
- 2015-03-30 EP EP15720820.8A patent/EP3122781B1/fr active Active
- 2015-03-30 EP EP19213494.8A patent/EP3699195A3/fr not_active Withdrawn
- 2015-03-30 BR BR112016022385-3A patent/BR112016022385A2/pt not_active Application Discontinuation
- 2015-03-30 KR KR1020167029551A patent/KR102327996B1/ko active Active
- 2015-03-30 DK DK15720820.8T patent/DK3122781T3/da active
- 2015-03-30 PE PE2016001729A patent/PE20161431A1/es unknown
- 2015-03-30 PL PL15720820T patent/PL3122781T3/pl unknown
- 2015-03-30 KR KR1020217023950A patent/KR102497443B1/ko active Active
- 2015-03-30 HU HUE15720820A patent/HUE048734T2/hu unknown
- 2015-03-30 TN TNP/2017/000532A patent/TN2017000532A1/en unknown
- 2015-03-30 IL IL248007A patent/IL248007B/en unknown
- 2015-03-30 EP EP21172032.1A patent/EP3954713A3/fr active Pending
- 2015-03-30 JP JP2016559176A patent/JP6775422B2/ja active Active
- 2015-03-30 SI SI201531079T patent/SI3122781T1/sl unknown
- 2015-03-30 ES ES15720820T patent/ES2775431T3/es active Active
- 2015-03-30 SM SM20200141T patent/SMT202000141T1/it unknown
- 2015-03-30 US US14/673,695 patent/US9822186B2/en active Active
- 2015-03-30 CR CR20160506A patent/CR20160506A/es unknown
- 2015-03-30 CN CN201911247777.7A patent/CN111410691B/zh active Active
- 2015-03-30 SG SG11201607983YA patent/SG11201607983YA/en unknown
- 2015-03-30 ME MEP-2020-43A patent/ME03666B/fr unknown
- 2015-03-30 HR HRP20200164TT patent/HRP20200164T1/hr unknown
- 2015-03-30 KR KR1020237004018A patent/KR20230022270A/ko not_active Ceased
- 2015-03-30 EA EA201691925A patent/EA201691925A1/ru unknown
- 2015-03-30 PT PT157208208T patent/PT3122781T/pt unknown
- 2015-03-30 CA CA2943621A patent/CA2943621A1/fr active Pending
- 2015-03-30 RS RS20200150A patent/RS59907B1/sr unknown
- 2015-03-30 AP AP2016009475A patent/AP2016009475A0/en unknown
- 2015-03-30 CN CN201580016659.9A patent/CN106471009B/zh active Active
- 2015-03-30 WO PCT/US2015/023411 patent/WO2015149077A1/fr not_active Ceased
- 2015-03-30 UA UAA201610778A patent/UA119167C2/uk unknown
- 2015-03-30 AU AU2015237184A patent/AU2015237184B2/en not_active Ceased
- 2015-03-30 SG SG10202008629XA patent/SG10202008629XA/en unknown
- 2015-03-30 MX MX2016012578A patent/MX385936B/es unknown
- 2015-03-30 LT LTEP15720820.8T patent/LT3122781T/lt unknown
2016
- 2016-09-27 MX MX2021010413A patent/MX2021010413A/es unknown
- 2016-09-27 PH PH12016501908A patent/PH12016501908A1/en unknown
- 2016-09-28 CL CL2016002460A patent/CL2016002460A1/es unknown
2017
- 2017-10-17 US US15/786,252 patent/US10858451B2/en active Active
2020
- 2020-03-06 CY CY20201100205T patent/CY1123236T1/el unknown
- 2020-10-06 JP JP2020169262A patent/JP7273016B2/ja active Active
- 2020-10-30 US US17/086,213 patent/US11840579B2/en active Active
2021
- 2021-02-25 AU AU2021201249A patent/AU2021201249A1/en not_active Abandoned
2023
- 2023-01-30 JP JP2023012047A patent/JP2023052766A/ja active Pending

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130209355A1 (en) *	2010-06-09	2013-08-15	Genmab A/S	Antibodies against human cd38
WO2012131555A2 (fr) *	2011-03-25	2012-10-04	Glenmark Pharmaceuticals S.A.	Immunoglobulines hétéro-dimériques
WO2014110601A1 (fr) *	2013-01-14	2014-07-17	Xencor, Inc.	Nouvelles protéines hétérodimères
US20140294833A1 (en) *	2013-01-14	2014-10-02	Xencor, Inc.	Novel heterodimeric proteins
WO2016086189A2 (fr) *	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimériques se liant à l'antigène cd3 et à un antigène tumoral
WO2016086196A2 (fr) *	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38

Also Published As

Publication number	Publication date
CN111410691A (zh)	2020-07-14
ES2775431T3 (es)	2020-07-27
SMT202000141T1 (it)	2020-05-08
EP3122781B1 (fr)	2020-01-01
AU2015237184A1 (en)	2016-10-20
US9822186B2 (en)	2017-11-21
KR20230022270A (ko)	2023-02-14
MX2016012578A (es)	2017-04-13
SG11201607983YA (en)	2016-10-28
KR102327996B1 (ko)	2021-11-17
US20180094079A1 (en)	2018-04-05
JP2021000141A (ja)	2021-01-07
IL248007B (en)	2022-07-01
CL2016002460A1 (es)	2018-05-11
PT3122781T (pt)	2020-03-05
TN2017000532A1 (en)	2019-04-12
CN106471009A (zh)	2017-03-01
UA119167C2 (uk)	2019-05-10
CA2943621A1 (fr)	2015-10-01
AP2016009475A0 (en)	2016-09-30
EP3122781A1 (fr)	2017-02-01
MX2021010413A (es)	2021-09-14
JP2017511130A (ja)	2017-04-20
HUE048734T2 (hu)	2020-08-28
US20150307629A1 (en)	2015-10-29
EA201691925A1 (ru)	2017-06-30
HRP20200164T1 (hr)	2020-05-01
PH12016501908A1 (en)	2017-01-09
EP3699195A3 (fr)	2020-11-04
JP2023052766A (ja)	2023-04-12
CN111410691B (zh)	2024-02-13
MX385936B (es)	2025-03-11
BR112016022385A2 (pt)	2018-06-19
RS59907B1 (sr)	2020-03-31
EP3954713A2 (fr)	2022-02-16
US10858451B2 (en)	2020-12-08
WO2015149077A1 (fr)	2015-10-01
PL3122781T3 (pl)	2020-06-15
DK3122781T3 (da)	2020-03-16
CY1123236T1 (el)	2020-11-25
KR20160136422A (ko)	2016-11-29
EP3699195A2 (fr)	2020-08-26
JP7273016B2 (ja)	2023-05-12
PE20161431A1 (es)	2017-01-22
ME03666B (fr)	2020-10-20
CN106471009B (zh)	2020-01-03
IL248007A0 (en)	2016-11-30
AU2021201249A1 (en)	2021-04-15
CR20160506A (es)	2017-03-10
AU2015237184B2 (en)	2020-11-26
KR102497443B1 (ko)	2023-02-08
KR20210097222A (ko)	2021-08-06
SG10202008629XA (en)	2020-10-29
US11840579B2 (en)	2023-12-12
JP6775422B2 (ja)	2020-10-28
LT3122781T (lt)	2020-03-25
SI3122781T1 (sl)	2020-03-31
US20210309762A1 (en)	2021-10-07

Publication	Publication Date	Title
EP3954713A3 (fr)	2022-03-30	Anticorps bispécifiques se liant à cd38 et cd3
CY1124993T1 (el)	2023-01-05	Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
PH12017500982A1 (en)	2018-01-08	Heterodimeric antibodies that bind cd3 and cd38
PH12017502019A1 (en)	2018-04-02	Heterodimeric antibodies that bind cd3 and tumor antigens
PH12018500711A1 (en)	2018-10-15	Anti-pd1 antibodies and methods of use
HK40093127A (zh)	2024-01-05	结合cd3和肿瘤抗原的异二聚体抗体
HK40065611A (zh)	2022-08-05	结合cd3和肿瘤抗原的异二聚体抗体

Legal Events

Date	Code	Title	Description
2022-01-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-01-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2022-02-16	AC	Divisional application: reference to earlier application	Ref document number: 3122781 Country of ref document: EP Kind code of ref document: P Ref document number: 3699195 Country of ref document: EP Kind code of ref document: P
2022-02-16	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-02-25	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2022-03-30	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-03-30	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/30 20060101ALI20220221BHEP Ipc: C07K 16/28 20060101ALI20220221BHEP Ipc: C07K 16/46 20060101AFI20220221BHEP
2022-10-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-11-09	17P	Request for examination filed	Effective date: 20220930
2022-11-09	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230411
2023-12-06	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: XENCOR, INC.